Healthcare Global Enterprises Limited (HCG), a leading provider of cancer care in India, is set to increase its stake in its step-down subsidiary, Cancer Care Kenya Limited (CCK).
Following an approval by its board of directors, the provider will acquire a further 10% shareholding in CCK. The investment, which is valued at Sh102.12 million, is set to be complete by the end of the first quarter of 2026.
Cancer Care Kenya, which has been operational since 2007, runs a full-fledged cancer hospital in Nairobi. The facility provides a critical range of services from radiation and chemotherapy to a dedicated 15-bed Day Care Centre. CCK’s financial trajectory is one of the reasons behind HCG’s increased interest.
The subsidiary has demonstrated explosive growth, with revenues catapulting from Sh132.34 million in 2023 to an impressive Sh620.55 million in 2025. This remarkable performance has further been solidified by a profit after tax of Sh158.12 million. According to Dr. B.S. Ajaikumar, HCG’s Founder and Executive Chair, the investment in CCK is part of a broader vision to transcend geographical boundaries.
“Our investment in Cancer Care Kenya Limited aligns with our vision of bringing advanced cancer care to more patients across borders. We see significant potential in the Kenyan market and are committed to supporting CCK’s growth and expansion plans,” said Dr. B.S. Ajaikumar.
HCG will further fortify CCK’s position by providing a guarantee in the form of a standby letter of credit. This financial instrument will secure a term loan of Sh232.65 million ($1.8 million) for CCK, fueling its business expansion ambitions.
For HCG, this guarantee represents a contingent liability, with its potential exposure limited to 105% of the outstanding loan amount. This comprehensive support package highlights a strategic bet on the continued growth of specialized healthcare in East Africa.
This initiative is widely seen as a potential springboard for further expansion across the African continent. HCG’s next steps will act as a focal point for investors and industry watchers alike, who are keen to gauge the impact of these international forays on the company’s long-term growth and market standing.
